The J591 antibody is widely used to target PSMA for NIRF imaging of prostate cancer (PCa), but owing to slow clearance of the full-length antibody from the blood, high signal-to-noise ratios can be achieved only several days post-injection (p.i.), which is not convenient for clinical applications. This evidence concerns the gene FOLH1 and prostate cancer.